**Supplemental Table 2.** Factors in univariate analysis

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | |  | **Overall Survival (months)** | | | **Progression-free Survival (months)** | |  |
| ***N*** | **Median (95% CI)** | **HR (95% CI)** | ***P*** | **Median (95% CI)** | **HR (95% CI)** | ***P*** |
| **Age (years)** | *≤65* | *125* | 8.7 (6.2-11.3) | 1.00 |  | 3.6 (2.6-4.5) | 1.00 |  |
| *>65* | *108* | 8.7 (6.9-10.5) | 1.10 (0.83-1.46) | *0.51* | 2.8 (2.5-3.1) | 1.33 (1.02-1.74) | ***0.04*** |
| **Gender** | *Male* | *156* | 8.7 (6.8-10.6) | 1.00 |  | 3.0 (2.7-3.3) | 1.00 |  |
|  | *Female* | *77* | 8.8 (7.0-10.5) | 1.00 (0.74-1.35) | *0.99* | 4.0 (2.2-5.8) | 0.98 (0.73-1.30) | *0.86* |
| **Prior nephrectomy** | *Yes* | *186* | 8.7 (7.0-10.5) | 1.00 |  | 3.3 (2.7-3.8) | 1.00 |  |
| *No* | *47* | 6.9 (2.8-11.0) | 1.27 (0.90-1.80) | *0.18* | 3.3 (2.8-3.7) | 1.05 (0.75-1.47) | *0.80* |
| **Histology** | *Clear cell* | *195* | 8.7 (7.3-10.1) | 1.00 |  | 2.9 (2.6-3.2) | 1.00 |  |
|  | *Non clear cell* | *19* | 7.8 (5.8-9.7) | 1.09 (0.66-1.80) | *0.74* | 4.6 (3.0-6.2) | 0.88 (0.55-1.42) | *0.60* |
| **Karnofsky status** | *≥ 80%* | *160* | 10.9 (8.2-13.5) | 1.00 |  | 4.1 (2.9-5.2) | 1.00 |  |
|  | *< 80%* | *73* | 5.1 (3.9-6.2) | 2.18 (1.61-2.94) | ***<0.001*** | 2.8 (2.5-3.0) | 1.87 (1.40-2.50) | ***<0.001*** |
| **Time from diagnosis to treatment** | *≥ 1 year* | *83* | 10.9 (7.0-14.7) | 1.00 |  | 4.0 (2.6-5.4) | 1.00 |  |
| *< 1 year* | *150* | 7.2 (5.5-8.9) | 1.34 (1.00-1.81) | *0.05* | 3.2 (2.8-3.5) | 1.11 (0.84-1.47) | *0.47* |
| **Baseline hemoglobin** | *≥ LLN* | *93* | 12.2 (7.8-16.5) | 1.00 |  | 4.0 (2.4-5.6) | 1.00 |  |
|  | *< LLN* | *140* | 6.7 (5.7-7.7) | 1.93 (1.43-2.60) | ***<0.001*** | 2.8 (2.7-2.9) | 1.57 (1.19-2.01) | ***0.002*** |
| **Baseline alb.corrected Ca** | *≤ ULN* | *177* | 9.1 (7.2-11.0) | 1.00 |  | 3.4 (2.6-4.2) | 1.00 |  |
|  | *>ULN* | *53* | 7.5 (4.7-10.3) | 1.11 (0.79-1.56) | *0.54* | 2.8 (2.4-3.3) | 1.28 (0.93-1.76) | *0.13* |
| **Baseline thrombocytes** | *≤ ULN* | *189* | 9.1 (4.9-9.7) | 1.00 |  | 3.2 (2.7-3.6) | 1.00 |  |
|  | *>ULN* | *44* | 7.3 (4.9-9.7) | 1.25 (0.88-1.78) | *0.21* | 3.5 (1.1-3.6) | 1.08 (0.76-1.52) | *0.68* |
| **Baseline sodium** | *≥ LLN* | *168* | 10.3 (8.1-12.5) | 1.00 |  | 3.5 (2.7-4.4) | 1.00 |  |
| *< LLN* | *65* | 6.1 (4.8-7.5) | 1.87 (1.37-2.57) | ***<0.001*** | 2.8 (2.7-3.0) | 1.36 (1.01-1.83) | ***0.04*** |
| **Baseline neutrophils** | *≤ ULN* | *193* | 9.8 (8.4-11.3) | 1.00 |  | 3.6 (2.6-4.5) | 1.00 |  |
| *>ULN* | *40* | 3.7 (2.4-5.0) | 2.38 (1.64-3.44) | ***<0.001*** | 2.6 (2.2-3.1) | 1.90 (1.33-2.71) | ***<0.001*** |
| **No. of previous treatment lines** | *1* | *111* | 7.4 (5.3-9.5) | 1.00 |  | 3.0 (2.5-3.5) | 1.00 |  |
| *≥2* | *122* | 9.8 (7.1-12.5) | 0.67 (0.50-0.89) | ***0.01*** | 3.5 (2.6-4.4) | 0.77 (0.60-1.01) | *0.06* |
| **Highest sodium during treatment** | *≥ LLN* | *182* | 9.9 (8.3-11.5) | 1.00 |  | 4.0 (2.9-5.1) | 1.00 |  |
| *< LLN* | *41* | 5.4 (3.8-7.0) | 2.17 (1.50-3.13) | ***<0.001*** | 2.8 (2.6-3.0) | 1.89 (1.32-2.70) | ***<0.001*** |
| **IMDC for previously treated patients** | *Favorable* | *23* | 20.4 (15.1-25.7) | 1.00 |  | 11.3 (0.3-22.4) | 1.00 |  |
| *Intermediate* | *115* | 9.9 (7.9-11.9) | 1.67 (0.96-2.88) | *0.07* | 4.0 (2.6-5.4) | 1.38 (0.86-2.22) | *0.18* |
| *Poor* | *93* | 5.6 (4.2-7.1) | 3.09 (1.78-5.38) | ***<0.001*** | 2.8 (2.7-2.9) | 2.22 (1.37-3.59) | ***0.001*** |